Neoadjuvant Endpoints, Response Criteria Proposed.
Lung cancer experts propose using immune-related pathologic response criteria to evaluate lung tumors in neoadjuvant trials of checkpoint inhibitors, and suggest using major pathologic response as a surrogate endpoint for all preoperative lung cancer studies.